Published on 30 Sep 2024 on Benzinga · via Yahoo Finance
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased...
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
Truist Securities raised the price target for Corcept Therapeutics Incorporated (NASDAQ:CORT) and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it “is impressive and difficult to ignore.”
Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who cannot have surgery or for whom surgery has failed.